ended 30 September 2020 are as follows: change Q3/2020 Q3/2019 increase (decrease) Sales 277.7 172.6 60.9% Other income 2.5 4.1 -39.9% Cost of sales - 207.6 - 159.6 -30.1% Selling expenses - 7.9 - 4.5

25.57 Net Profit Margin (%) 2.40 2.35 3.16 Current Ratio (Times) 1.43 1.43 1.40 Debt to Equity Ratio (Times) 1.79 1.81 1.89 Book Value per Share (Baht) 2.22 2.25 2.25 Net Profit per Share (Baht) 0.45 0.43

Total Expenses 4,334.0 65.1 4,697.1 69.2 363.1 8.4 Profit before share of loss from investments in joint ventures, finance cost and income tax expenses 2,323.2 34.9 2,092.7 30.8 (230.6) (9.9) Share of

Item Quarter Change (%) H1 Change 2/2017 1/2017 2/2016 1/2017 2/2016 2017 2016 (%) Net profit * 8,047 8,305 7,169 (3.1)% 12.2% 16,352 15,487 5.6% Earnings per share (Baht) 4.22 4.35 3.76 (3.1)% 12.2

2017 the Company organized such event in the fourth quarter (during November), resulting in a decrease in net profit ratio (ROS) from 20.16% in 2017 to 17.16% in 2018, for the same period. The total

Increase/(Decrease) For Three Months Ended 31 March 2019 2020 THB mm % THB mm % THB mm % Sale Revenue Revenue from selling product under Company’s trademark 1) Skincare 163.28 75.09 92.33 43.39 (70.95

revenue from sales and services amounted to Baht 7,815 million, decreased by Baht 334 million or 4% QoQ. This result from the decrease in sale volume and selling price while increase in production cost both

be a potential market in the future. For Medical Devices; There is still intense competition in both domestic and foreign markets. Market leaders use price strategies to gain market share. But the

-355.1 -5.0% Gross Profit 707.7 1,026.1 -318.4 -31.0% Gross Profit Margin (%) 9.5% 12.6% -3.1% SG&A expenses 459.9 440.4 19.5 4.4% Loss on exchange rate 0.0 35.4 -35.4 -100.0% EBIT before share of profit

its subsidiaries (the “Company”) has recently submitted the reviewed interim financial statements for the period ended 30 September 2017 to the Stock Exchange of Thailand with a view to share the